Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jin Shu
Institution:
BridgeBio Oncology Therapeutics (United States)
Observed institution:
BridgeBio Oncology Therapeutics (United States)
ORCID:
0009-0000-2487-3613
Observed ORCID:
0009-0000-2487-3613
OpenAlex ID:
A5138828280
Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
·
Cancer Discovery
·
12
Abstract 7104: BBO-11818: An orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models
2026
·
Carlos E. Stahlhut Espinosa
, Anna E. Maciag
, et al.
·
Cancer Research
·
1
Supplementary Figure S2 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S5 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S3 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Suppl. Materials and Methods 1 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S7 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Table S2 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S1 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S4 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S8 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Table S3 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Table S1 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S6 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S6 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S7 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Table S2 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S5 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S1 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S2 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S3 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Data from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S8 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Table S1 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S4 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Show more works
View as search
Works count:
27
Citation count:
13
H-index:
1
I10-index:
1
Year
Topic
Type